Literature DB >> 14592267

Hypercoagulability in patients with obstructive sleep apnea.

J J Guardiola1, P J Matheson, L C Clavijo, M A Wilson, E C Fletcher.   

Abstract

BACKGROUND: Obstructive sleep apnea (OSA) has been linked to cardiovascular complications such as stroke and myocardial infarction. Previous studies demonstrate that OSA patients show elevated fibrinogen levels and increased platelet aggregation that are reversed with 1 night of nasal continuous positive airway pressure treatment (NCPAP). Questioning overall coagulability in OSA, we examined whole blood coagulability in 11 chronically NCPAP treated OSA subjects, 22 previously untreated OSA subjects, and in 16 of these after 1 night of NCPAP treatment. PATIENTS AND METHODS: During full polysomnography, subjects from each group had blood drawn prior to bedtime (21:00 h) and upon waking in the morning (07:00 h).
RESULTS: Untreated OSA patients had faster P.M. clotting times than chronically treated OSA patients (3.33+/-0.31 versus 6.12+/- 0.66 min, P<0.05 by ANOVA). A.M. values showed similar results (4.31+/- 0.34 min versus 7.08+/-0.52 min, P<0.05 by ANOVA) for the respective groups. One overnight treatment with nasal CPAP did not produce a significant change in A.M. whole blood coagulability (4.35 +/-0.43 to 5.31+/-0.53 min; n=16; P=0.1) in 16 treated subjects.
CONCLUSIONS: These data indicate a relationship between obstructive sleep apnea and blood hypercoagulability status that appears to be reversed by chronic NCPAP treatment. These data suggest that NCPAP might protect against the development of cardiovascular complications in OSA patients.

Entities:  

Year:  2001        PMID: 14592267     DOI: 10.1016/s1389-9457(01)00088-0

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  13 in total

Review 1.  Coagulability in obstructive sleep apnea.

Authors:  Christina Liak; M Fitzpatrick
Journal:  Can Respir J       Date:  2011 Nov-Dec       Impact factor: 2.409

2.  The effect of acute aerobic exercise on hemostasis in obstructive sleep apnea.

Authors:  Ryan A Martin; Courtney Strosnider; Gabrielle Giersch; Christopher J Womack; Trent A Hargens
Journal:  Sleep Breath       Date:  2017-02-14       Impact factor: 2.816

Review 3.  Sleep disorders and the risk of stroke.

Authors:  Mollie McDermott; Devin L Brown; Ronald D Chervin
Journal:  Expert Rev Neurother       Date:  2018-06-25       Impact factor: 4.618

Review 4.  Obstructive sleep apnea syndrome: coagulation anomalies and treatment with continuous positive airway pressure.

Authors:  Domenico Maurizio Toraldo; Michele De Benedetto; Egeria Scoditti; Francesco De Nuccio
Journal:  Sleep Breath       Date:  2015-07-14       Impact factor: 2.816

Review 5.  Inflammation in sleep apnea: an update.

Authors:  Dileep Unnikrishnan; Jonathan Jun; Vsevolod Polotsky
Journal:  Rev Endocr Metab Disord       Date:  2015-03       Impact factor: 6.514

6.  Sleep apnea is common in patients with coronary artery disease.

Authors:  Christian Prinz; Thomas Bitter; Cornelia Piper; Dieter Horstkotte; Lothar Faber; Olaf Oldenburg
Journal:  Wien Med Wochenschr       Date:  2010-07

7.  Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension.

Authors:  Carlos Zamarrón; Jorge Ricoy; Alberto Riveiro; Francisco Gude
Journal:  Lung       Date:  2008-03-11       Impact factor: 2.584

8.  Severity of obstructive sleep apnea is associated with elevated plasma fibrinogen in otherwise healthy patients.

Authors:  Abu Shamsuzzaman; Raouf S Amin; Andrew D Calvin; Diane Davison; Virend K Somers
Journal:  Sleep Breath       Date:  2014-02-09       Impact factor: 2.816

9.  Assessment of multiple health risks in a single obstructive sleep apnea population.

Authors:  David W Hudgel; Lois E Lamerato; Gordon R Jacobsen; Christopher L Drake
Journal:  J Clin Sleep Med       Date:  2012-02-15       Impact factor: 4.062

10.  Associations between Cardioembolic Stroke and Obstructive Sleep Apnea.

Authors:  Melissa C Lipford; Kelly D Flemming; Andrew D Calvin; Jay Mandrekar; Robert D Brown; Virend K Somers; Sean M Caples
Journal:  Sleep       Date:  2015-11-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.